Department of Radiation Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio.
Department of Breast Surgery, Cleveland Clinic, Cleveland, Ohio.
Breast J. 2019 Nov;25(6):1071-1078. doi: 10.1111/tbj.13428. Epub 2019 Jul 1.
Salvage mastectomy (SM) is the standard of care for patients with local recurrence (LR) after breast conservation therapy (BCT), often with immediate reconstruction. Complications of reconstruction are a concern for these patients, and long-term data are limited. We sought to compare rates of complications requiring re-operation (CRR) and reconstruction failure (RF) between autologous reconstruction (AR) and tissue expander/implant reconstruction (TE/I). Patients with locally recurrent breast cancer after BCT, treated with SM and immediate AR or TE/I between 2000 and 2008, were identified. CRR was defined as unplanned return to operating room for wound infection, dehiscence, necrosis (including flap, skin, or fat), hematoma, or hernia (for AR) and extrusion, leak, or capsular contracture (for TE/I). RF was defined as conversion to another reconstruction technique or to flat chest wall. This study included 103 patients with 107 reconstructions. Median follow-up was 6.6 years. CRR and RF were significantly higher with TE/I (n = 34) compared to AR (n = 73) at 5 years (50.9% vs 25.5%; P = 0.02) and (42.1% vs 5.8%; P < 0.001). On univariate analysis (UVA), TE/I (HR = 2.14; P = 0.02) and diabetes (HR = 5.10; P = 0.007) were significant predictors for CRR. On UVA, TE/I (HR = 7.30; P < 0.001) and older age at reconstruction (HR = 1.03; P = 0.003) were significant predictors for RF. In this population of previously irradiated patients, TE/I was associated with significantly higher CRR and RF. Complications continue to occur up to 10 years after TE/I. AR should be considered in appropriately selected patients, though TE/I may remain a reasonable option in patients without high-risk factors for surgical complications.
挽救性乳房切除术(SM)是保乳治疗(BCT)后局部复发(LR)患者的标准治疗方法,通常需要立即进行重建。这些患者对重建并发症感到担忧,长期数据有限。我们旨在比较自体重建(AR)和组织扩张器/植入物重建(TE/I)之间需要再次手术的并发症发生率(CRR)和重建失败率(RF)。我们确定了 2000 年至 2008 年间接受 BCT 后局部复发乳腺癌治疗的 SM 和即刻 AR 或 TE/I 的患者。CRR 定义为因伤口感染、裂开、坏死(包括皮瓣、皮肤或脂肪)、血肿或疝(用于 AR)和挤出、泄漏或包膜挛缩(用于 TE/I)而计划外返回手术室。RF 定义为转换为另一种重建技术或扁平胸壁。这项研究包括 103 例患者共 107 例重建。中位随访时间为 6.6 年。5 年时,TE/I(n=34)的 CRR 和 RF 明显高于 AR(n=73)(50.9%比 25.5%;P=0.02)和(42.1%比 5.8%;P<0.001)。在单变量分析(UVA)中,TE/I(HR=2.14;P=0.02)和糖尿病(HR=5.10;P=0.007)是 CRR 的显著预测因素。在 UVA 中,TE/I(HR=7.30;P<0.001)和重建时年龄较大(HR=1.03;P=0.003)是 RF 的显著预测因素。在这群先前接受过放疗的患者中,TE/I 与更高的 CRR 和 RF 显著相关。TE/I 后的并发症可继续发生长达 10 年。在适当选择的患者中应考虑 AR,尽管对于手术并发症高危因素的患者,TE/I 可能仍然是一个合理的选择。